Give the screens a rest for a wee bit. View Entire Post › ...
Adding small or even large amounts of saturation doesn’t have to be bad for you, as we explore how to singe your sonics ...
Screen-free spaces that promote mindful relaxation and face-to-face connection have become increasingly popular over the last year Natalia Senanayake is an Editorial Assistant, Lifestyle at PEOPLE.
Roche once again tapped its Chinese partner MediLink for another antibody-drug conjugate to be studied across several solid tumor types, nearly two years to the day after first partnering. Roche is ...
Antibody drug conjugates (ADCs) mark a new era in targeted cancer therapy, delivering potent cytotoxic chemotherapy via monoclonal antibodies directly into the tumor cells — an era with potentially ...
From Roche’s $1.4 billion licensing deal to AstraZeneca’s presidential symposium and an avalanche of clinical readouts, antibody-drug conjugates dominated Europe’s leading cancer conference over the ...
Antibody-drug conjugates (ADCs) are a mature technology. The first ADC, Mylotarg, was initially approved in 2000, and there are now 14 approved agents in both leukemias and solid tumors. According to ...
ADC usage in breast cancer treatment increased 3.7-fold from 2021 to 2023, with significant reductions in median time to treatment. Older women experience lower ADC treatment rates and longer delays ...
BEIJING--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based ...
Abstract: Growing serial I/O data rates, over both severe low-pass electrical and dispersive optical channels, necessitate increased equalization complexity and consideration of more ...
Explore how digital feedback controllers manage motors, pressure, temperature, and more, and learn why ADC and DAC performance are crucial when designing robust embedded systems. How to define the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results